Supplementary data: Perceptions of indirect treatment comparisons as an evidence base in oncology decision-making: results of an international survey of health technology assessment and payer decision-makers

These are peer-reviewed supplementary materials for the article 'Perceptions of indirect treatment comparisons as an evidence base in oncology decision-making: results of an international survey of health technology assessment and payer decision-makers' published in the Journal of Comparative Effectiveness Research.Supplementary Table 1: Question theme and types of questionsQuestionnaire: Payer perceptions and use of ITC in HTA/P&R decision-makingAim: Health technology assessment (HTA) and payer organizations are often faced with early decision making in oncology. To design and conduct robust indirect treatment comparisons (ITCs), it is important to better understand HTA and payer decision-maker perceptions of ITCs. Here we aim to describe what individuals with HTA and payer experience see as the acceptability of ITCs for HTA and payer organization coverage and reimbursement decision-making. Materials & methods: This survey included 30 current and former HTA and payer decision-makers from five countries: Australia, France, Germany, the UK (n = 5 each) and the US (n = 10). Main outcomes included the ratings of acceptance of ITCs and the presence of welldefined methodological guidance for ITCs. Results: ITCs are generally accepted by participants in Australia and the UK but are more likely evaluated on a case-by-case basis in France, Germany and the US. Four of five participants in Germany and the UK, two of five in Australia and one of five in France reported that well-defined and prescribed criteria regarding the use of ITCs were in place. Conclusion: There is a need for harmonization of methods used to assess ITCs by HTA and payers, especially in the rapidly evolving treatment landscape in oncology.

本数据集为发表于《比较效果研究杂志》的论文《在肿瘤学决策中，对间接治疗比较作为证据基础的认识：国际健康技术评估和支付决策者的调查结果》的同行评审补充材料。补充表1：问卷主题和问题类型问卷：支付者对间接治疗比较在健康技术评估/支付与再保险决策中的应用的看法目标：健康技术评估（HTA）和支付机构在肿瘤学领域往往需要面对早期决策。为了设计和实施稳健的间接治疗比较（ITC），深入了解HTA和支付决策者对ITC的看法至关重要。本研究旨在描述具有HTA和支付经验的个体如何看待ITC在HTA和支付机构覆盖和报销决策中的可接受性。研究方法：本调查包括来自五个国家的30名当前和前任HTA及支付决策者：澳大利亚、法国、德国、英国（各5名）和美国（10名）。主要结果包括对ITC接受度的评分和是否存在明确的方法论指导。结果：ITC在澳大利亚和英国的参与者中普遍得到认可，但在法国、德国和美国更可能根据个案进行评估。德国和英国的参与者中有五分之四，澳大利亚中有五分之二，法国中有五分之一报告称，有关ITC使用的明确和规定的标准已到位。结论：在肿瘤学快速发展的治疗领域中，需要协调HTA和支付者评估ITC所使用的方法。